Hydroxyurea Resistant Polycythemia Vera
January 2015
April 2015
July 2015
October 2015
January 2016
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More